This course is still available as a learning tool but has expired for CME credit.
The management of patients with rheumatoid arthritis actively evolves as further evidence-based data becomes available. The relatively recent development of biologics and DMARDS has presented new challenges in clinical decision making for the busy rheumatologist. This program is designed to provide a review of immunology science which is necessary for an in-depth discussion of DMARDS efficacy and safety data. The program will cover treating-to-target as well as recent head-to-head non-inferiority clinical trials that have presented important information for professionals who care for patients with rheumatoid arthritis. This CME program will help all rheumatologists care for the RA patient.
This activity was designed to meet the needs of rheumatologists, primary care physicians, internists, and other healthcare professionals who care for patients with RA.
Upon completion of this activity, participants will be able to:
- Discuss the updated ACR guidelines, and advances in evidence-based medicine of rheumatoid arthritis.
- Evaluate clinical trial data for rheumatoid arthritis therapies, including biologic therapies, with a particular focus on head-to-head clinical trials.
- Apply personalized patient management strategies that utilize treat-to-target goals.